| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $11,287,500 | 1 | 100 |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 0 | $0 | 1 | $11.29M | $-11.29M |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Over the last 12 months, insiders at Inhibrx Biosciences, Inc. have bought $0 and sold $11.29M worth of Inhibrx Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Inhibrx Biosciences, Inc. have bought $17.39M and sold $8.35M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 18,750 shares for transaction amount of $266,102 was made by Kayyem Jon Faiz (director) on 2024‑11‑20.
| 2025-10-07 | Sale | VIKING GLOBAL INVESTORS LP | 10 percent owner | 350,000 2.3261% | $32.25 | $11.29M | +133.00% | |
| 2024-11-20 | Kayyem Jon Faiz | director | 18,750 0.1292% | $14.19 | $266,102 | +5.59% | ||
| 2024-11-19 | Kayyem Jon Faiz | director | 34,843 0.2402% | $14.23 | $495,708 | +3.39% | ||
| 2024-10-03 | Vuori Kristiina MD | director | 6,667 0.0451% | $15.00 | $100,005 | -1.38% | ||
| 2024-09-16 | Lappe Mark | Chief Executive Officer | 13,037 0.0885% | $17.13 | $223,324 | -15.81% | ||
| 2024-09-12 | Lappe Mark | Chief Executive Officer | 26,963 0.1859% | $15.05 | $405,793 | -2.69% | ||
| 2024-09-11 | Vuori Kristiina MD | director | 6,457 0.0443% | $15.07 | $97,307 | -2.17% | ||
| 2024-09-10 | Lappe Mark | Chief Executive Officer | 8,500 0.0588% | $15.19 | $129,115 | -3.33% | ||
| 2024-09-10 | Vuori Kristiina MD | director | 179 0.0012% | $15.00 | $2,685 | -3.33% | ||
| 2024-09-09 | Lappe Mark | Chief Executive Officer | 9,500 0.0657% | $15.21 | $144,495 | -3.45% | ||
| 2024-09-06 | Lappe Mark | Chief Executive Officer | 26,000 0.1824% | $15.29 | $397,540 | -2.59% | ||
| 2024-05-28 | Sale | Eckelman Brendan P. | Chief Scientific Officer | 300,000 0.5717% | $34.30 | $10.29M | -57.94% | |
| 2023-08-28 | VIKING GLOBAL INVESTORS LP | 10 percent owner | 511,627 1.13% | $19.35 | $9.9M | +15.05% | ||
| 2023-03-01 | Sale | Eckelman Brendan P. | Chief Scientific Officer | 40,000 0.1006% | $24.21 | $968,231 | -5.04% | |
| 2023-02-28 | Sale | Lappe Mark | Chief Executive Officer | 60 0.0002% | $25.02 | $1,501 | -5.41% | |
| 2023-02-02 | Sale | Eckelman Brendan P. | Chief Scientific Officer | 11,250 0.0285% | $25.45 | $286,355 | -9.28% | |
| 2023-02-01 | Sale | Eckelman Brendan P. | Chief Scientific Officer | 28,750 0.0707% | $24.73 | $710,856 | -9.21% | |
| 2023-01-24 | Sale | Lappe Mark | Chief Executive Officer | 4,335 0.0103% | $25.72 | $111,478 | -15.76% | |
| 2023-01-23 | Sale | Kayyem Jon Faiz | director | 9,500 0.0235% | $25.26 | $239,999 | -10.60% | |
| 2023-01-23 | Sale | Lappe Mark | Chief Executive Officer | 21,665 0.0538% | $25.36 | $549,364 | -10.60% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 67018 0.4608% | $4.8M | 4 | 1 | +25.58% |
| Shabet Rose Sharon | director | 2427307 16.6897% | $173.87M | 1 | 0 | <0.0001% |
| Eckelman Living Trust Dated February 5, 2014 | director | 2235553 15.3712% | $160.13M | 0 | 5 | |
| Eckelman Brendan P. | Chief Scientific Officer | 1735553 11.9333% | $124.32M | 0 | 10 | |
| Lappe Mark | Chief Executive Officer | 705548 4.8512% | $50.54M | 5 | 6 | <0.0001% |
| Wagner Klaus W. | Chief Medical Officer | 215150 1.4793% | $15.41M | 0 | 2 | |
| Kayyem Jon Faiz | director | 69843 0.4802% | $5M | 2 | 4 | +4.49% |
| Vuori Kristiina MD | director | 20443 0.1406% | $1.46M | 3 | 0 | <0.0001% |
$607,159,124 | 92 | 3.55% | $1.05B | |
$96,660,103 | 38 | -2.10% | $932.07M | |
$61,783,526 | 37 | 18.57% | $965.68M | |
$28,907,358 | 35 | 41.41% | $878.6M | |
$35,092,436 | 31 | 38.62% | $959.26M | |
$150,336,897 | 29 | -5.97% | $1.08B | |
$104,199,091 | 28 | 16.42% | $1.09B | |
$276,750,010 | 16 | -7.95% | $1.13B | |
$21,945,105 | 15 | -26.51% | $1.09B | |
Inhibrx, Inc. (INBX) | $48,220,484 | 14 | 2.13% | $1.04B |
$133,809,976 | 13 | 31.29% | $888.22M | |
$5,794,001 | 10 | 23.26% | $961.62M | |
$1,435,760 | 10 | 2.01% | $1.04B | |
$38,624,786 | 9 | 1.26% | $880.83M | |
$1,580,951 | 9 | -14.18% | $910.43M | |
$1,944,616 | 6 | 0.35% | $1.09B | |
$25,999,974 | 4 | 0.00% | $1.05B | |
$33,624,000 | 2 | -50.37% | $1.1B | |
$13,900 | 1 | -39.25% | $905.85M |
| Increased Positions | 83 | +74.77% | 3M | +33.05% |
| Decreased Positions | 47 | -42.34% | 1M | -11.04% |
| New Positions | 45 | New | 1M | New |
| Sold Out Positions | 10 | Sold Out | 259,839 | Sold Out |
| Total Postitions | 147 | +32.43% | 13M | +22.01% |
| Viking Global Investors Lp | $134,149.00 | 11.92% | 1.79M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $99,631.00 | 8.85% | 1.33M | +349,815 | +35.77% | 2025-09-30 |
| Sanofi | $86,891.00 | 7.72% | 1.16M | 0 | 0% | 2025-09-30 |
| Hightower Advisors, Llc | $65,417.00 | 5.81% | 871,759 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $51,383.00 | 4.57% | 684,746 | -43,998 | -6.04% | 2025-09-30 |
| Vanguard Group Inc | $44,643.00 | 3.97% | 594,918 | -3,530 | -0.59% | 2025-09-30 |
| Morgan Stanley | $33,232.00 | 2.95% | 442,856 | +415,048 | +1,492.55% | 2025-09-30 |
| Sofinnova Investments, Inc. | $33,025.00 | 2.93% | 440,092 | -268,586 | -37.9% | 2025-09-30 |
| Woodline Partners Lp | $25,258.00 | 2.24% | 336,590 | -326,278 | -49.22% | 2025-09-30 |
| Millennium Management Llc | $22,348.00 | 1.99% | 297,820 | +22,042 | +7.99% | 2025-09-30 |